Media & Press relations

Our latest press releases

April 17, 2025

First-Quarter 2025 Business Review

Consolidated sales totaled €1,098 million in the first quarter of 2025, up 13.7% as reported from €965 million in first quarter of 2024. Organic growth (at constant exchange rates and scope of consolidation) stood at +12.7%, above expectations.

Discover more

Swipe for more

April 07, 2025

bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship

bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of LUMED™ APSS™, an advanced clinical decision support system (CDSS) designed to enhance antimicrobial stewardship programs (ASP) and improve patient outcomes.

Read more
March 18, 2025

bioMérieux receives FDA 510(k) Clearance for its VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance

bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. Food and Drug Administration (FDA) 510(k) clearance for VITEK® COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring consumer safety.

Read more
March 07, 2025

bioMérieux – 2024 Financial Results

Consolidated sales amounted to €3,980 million in 2024, up 10.3% like-for-like from €3,675 million in the prior year period. Reported growth stood at +8.3% for the period.

Read more